Endonovo Therapeutics, Inc.

OTCPK:ENDV Stock Report

Market Cap: US$140.6k

Endonovo Therapeutics Valuation

Is ENDV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Share Price vs Fair Value

What is the Fair Price of ENDV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ENDV?

Key metric:

The above table shows the Price to Sales ratio for ENDV. This is calculated by dividing ENDV's market cap by their current revenue.
What is ENDV's PS Ratio?
PS Ratio0.5x
SalesUS$255.72k
Market CapUS$140.56k

Price to Sales Ratio vs Peers

How does ENDV's PS Ratio compare to its peers?

The above table shows the PS ratio for ENDV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.7x
HSTO.Q Histogen
6.4xn/aUS$115.3k
CAPS Capstone Holding
0.009xn/aUS$394.0k
NSTM NovelStem International
35.6xn/aUS$609.5k
THER Theralink Technologies
1xn/aUS$615.1k
ENDV Endonovo Therapeutics
0.5xn/aUS$140.6k

Price to Sales Ratio vs Industry

How does ENDV's PS Ratio compare vs other companies in the US Biotechs Industry?

139 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.9x18.2%
ENDV Endonovo Therapeutics
 0.5xn/aUS$140.56k
BIIB Biogen
2.2x1.2%US$21.31b
MRNA Moderna
3x10.2%US$15.79b
ENDV 0.5xIndustry Avg. 9.9xNo. of Companies139PS01632486480+
139 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.9x27.2%
ENDV Endonovo Therapeutics
 0.5xn/aUS$140.56k
No more companies

Price to Sales Ratio vs Fair Ratio

What is ENDV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ENDV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ration/a

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 00:26
End of Day Share Price 2025/01/31 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Endonovo Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullSeeThruEquity, LLC